PIG-F inhibitors, also known as phosphatidylinositol glycan class F inhibitors, belong to a specialized category of chemical compounds designed to target a specific enzymatic pathway within the cell membrane. These inhibitors are characterized by their ability to modulate the activity of the PIG-F enzyme, which plays a crucial role in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors. GPI anchors are complex glycolipids that serve as membrane anchors for a wide range of cell surface proteins, including receptors and adhesion molecules. The addition of GPI anchors is essential for the proper localization and functioning of these proteins on the cell surface.
PIG-F inhibitors involves interfering with the enzymatic reactions responsible for GPI anchor synthesis. By doing so, these inhibitors disrupt the normal process of anchoring proteins to the cell membrane. This targeted interference can have a profound impact on various cellular processes and signaling pathways, ultimately affecting cell adhesion, signal transduction, and the overall organization of cell membranes. PIG-F inhibitors are valuable tools in cellular and molecular biology research, enabling scientists to investigate the functions of GPI-anchored proteins and explore the consequences of their absence or malfunction. Additionally, the development and study of PIG-F inhibitors have provided valuable insights into the broader field of lipid biochemistry and membrane biology, contributing to our understanding of cell structure and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Targets VEGFR, which is part of the same family as PIGFR, potentially reducing PIGF-mediated angiogenesis. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits RAF kinase, VEGFR, and PDGFR, which are involved in downstream signaling of PIGF. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Blocks VEGFR, PDGFR, and c-KIT, affecting pathways that PIGF may be part of. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Targets VEGFR, which might interfere with PIGF-related signaling. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits multiple tyrosine kinases including VEGFR, potentially impacting PIGF-mediated effects. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Targets VEGFR amongst others, which could alter PIGF-related pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR, and indirectly could affect PIGF signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets EGFR, which could have downstream effects on PIGF signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Inhibits HER2 and EGFR, potentially influencing PIGF signaling indirectly. | ||||||